Ankylosing spondylitis: etiology, pathogenesis, and treatments
- PMID: 31666997
- PMCID: PMC6804882
- DOI: 10.1038/s41413-019-0057-8
Ankylosing spondylitis: etiology, pathogenesis, and treatments
Abstract
Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain; additionally, in more advanced cases, it can cause spine fusion. Significant progress in its pathophysiology and treatment has been achieved in the last decade. Immune cells and innate cytokines have been suggested to be crucial in the pathogenesis of AS, especially human leukocyte antigen (HLA)‑B27 and the interleukin‑23/17 axis. However, the pathogenesis of AS remains unclear. The current study reviewed the etiology and pathogenesis of AS, including genome-wide association studies and cytokine pathways. This study also summarized the current pharmaceutical and surgical treatment with a discussion of future potential therapies.
Keywords: Calcium and phosphate metabolic disorders; Pathogenesis.
© The Author(s) 2019.
Conflict of interest statement
Competing interestsThe authors declare no competing interests.
Figures
References
-
- Lindström U, Olofsson T, Wedrén S, Qirjazo I, Askling J. Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study. RMD open. 2018;4:e000762–e000762. doi: 10.1136/rmdopen-2018-000762. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
